

Press release

New Generation IBA Cyclotron To Fight Cancer

Embargo until 5:40 pm (Belgian time) – October 14, 2005

Louvain-la-Neuve, Belgium, October 14, 2005 – IBA (Ion Beam Applications S.A.: Reuters IOBAt.BR and Bloomberg IBAB.BB) announced today the sale of a new type of high-energy cyclotron (70 MeV – million-electron-volt) to be installed in the university hospital center the CHU in Nantes, France.

The cutting edge Cyclotron will be used for research, teaching and production of new generation radioisotopes that will enable the exploration of new perspectives in the field of cancer diagnosis and therapy. The project is headed by Nantes University, in partnership with its national (CNRS, INSERM) and local (Centre de lutte contre le cancer, Centre Hospitalier Universitaire, Ecole des Mines) partners.

This project is mainly financed by the “Pays de la Loire” French Regional Authority, contracting authority, and the French Ministry for Higher Education & Research, as well as European Structural Funds. The equipment is commissioned in the scope of the "Cancer Plan" initiated by the French government. The cyclotron will be delivered at the end of 2007 and put into service during the second half of 2008. For this new type of cyclotron, IBA is planning on working with vendors operating in certain high technology fields in the “Pays de la Loire” Region.

This contract of about €14 Million was awarded in the scope of an International Public Tender. IBA was selected for its capacity to design, build and install such equipment based on its unique expertise in the field of radioisotope production and its contribution to cyclotron’s technological breakthroughs over the past few years.

Pierre Mottet, IBA’s Chief Executive Officer, was delighted that the company was awarded this new contract *"that enables IBA to make headway in the field of new generation radioisotopes, opening new perspectives for cancer diagnosis and therapy. IBA's mission is to provide the tools required to fight cancer and this project is a renewed confirmation of its leadership in the field."*

About IBA

IBA delivers efficient, dependable solutions of a unique precision in the fields of cancer diagnosis and therapy. IBA provides radiopharmaceutical products, notably in the field of Positron Emission Tomography. The company also offers innovative responses to improve the efficacy, hygiene and safety of everyday life through sterilization and ionization solutions. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to BelSmall index. Website: <http://www.iba-worldwide.com>

Contact

IBA

Paul-Emmanuel Goethals

Director, Corporate Business Development
& Investor Relations

Tel.: +32 10 47 58 16

goethals@iba.be